Levosimendan in Trastuzumab-Induced Cardiotoxicity: A Mechanism-Based Perspective

Nazari Taloki, Zahra

Volume 17, Issue 3 (Summer 2026) Caspian J Intern Med 2026, 17(3): 688-689 | Back to browse issues page

Mendeley

Zotero

RefWorks

Nazari Taloki Z. Levosimendan in Trastuzumab-Induced Cardiotoxicity: A Mechanism-Based Perspective. Caspian J Intern Med 2026; 17 (3) :688-689
URL: http://caspjim.com/article-1-5081-en.html

Levosimendan in Trastuzumab-Induced Cardiotoxicity: A Mechanism-Based Perspective

Zahra Nazari Taloki ^*

Cancer Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran & Department of Clinical Pharmacy, School of Pharmacy, Babol University of Medical Sciences, Babol, Iran , zahra_nazari_taloki@yahoo.com

Abstract: (15 Views)

Trastuzumab is a cornerstone therapy in HER2-positive breast cancer, yet its association with cardiotoxicity remains a major limitation in clinical practice. Trastuzumab-induced cardiac dysfunction, although often considered non-necrotic and potentially reversible, frequently manifests as left ventricular ejection fraction decline and symptomatic heart failure, leading to treatment interruption and compromised oncologic outcomes (1, 2). These clinical challenges highlight the need for a proactive, mechanism-oriented strategy in managing trastuzumab-related cardiac adverse effects.

Keywords: Levosimendan, HER2 signaling, Trastuzumab, Cardiotoxicity, Mitochondrial dysfunction

Full-Text [PDF 293 kb] (7 Downloads)

Policy Brief: Letter to Editor | Subject: Oncology
Received: 2026/02/12 | Accepted: 2026/08/18 | Published: 2026/06/29